PPARs and the complex journey to obesity

Nature Medicine

Volumn 10, Issue 4, 2004, Pages 355-361

  Evans, Ronald M ^a   Barish, Grant D ^a,b   Wang, Yong Xu ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GHRELIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN RECEPTOR; MELANOCORTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GONIST; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN;

ADIPOCYTE; APPETITE; AUTOPHOSPHORYLATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY ACID OXIDATION; FOOD INTAKE; GENE TARGETING; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPODYSTROPHY; LIPOGENESIS; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; THERMOGENESIS; THERMOREGULATION; UPREGULATION; WEIGHT GAIN;

ADIPOCYTES; APPETITE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCOSE; HOMEOSTASIS; HUMANS; LIPIDS; OBESITY; RECEPTOR, INSULIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 1942518840     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1025     Document Type: Review

References (105)

1. Stunkard, A., Foch, T. & Hrubec, Z. A twin study of human obesity. JAMA 256, 51-54 (1986).
2. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
3. Tartaglia, L, et al. Identification and expression cloning of a leptin receptor OB-R. Cell 83, 1263-1271 (1995).
4. Seeley, R. & Woods, S. Monitoring of stored and available fuel by the CNS: implications for obesity. Nat. Rev. Neurosci. 4, 901-909 (2003).
5. Nakazato, M. et al. A role for ghrelin in the central regulation of feeding. Nature 409, 194-198 (2001).
6. Drazen, D. & Woods, S. Peripheral signals in the control of satiety and hunger. Curr. Opin. Clin. Nutr. Metab. Care 6, 621-629 (2003).
7. Batterham, R. et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418, 650-654 (2002).
8. Turton, M. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72 (1996).
9. Bachman, E. et al. βAR signaling required for diet-induced thermogenesis and obesity resistance. Science 297, 843-845 (2002).
10. Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98, 115-124 (1999).
11. Lin, J. et al. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 418, 797-801 (2002).
12. Lowell, B. & Spiegelman, B. Towards a molecular understanding of adaptive thermogenesis, Nature 404, 652-660 (2000).
13. Enerback, S. et al. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387, 90-94 (1997).
14. Fleury, C. et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet. 15, 269-272 (1997).
15. Gimeno, R.E. et al. Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 46, 900-906 (1997).
16. Boss, O. et al. Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett. 408, 39-42 (1997).
17. Vidal-Puig, A., Solanes, G., Grujic, D., Flier, J.S. & Lowell, B.B. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem. Biophys. Res. Commun. 235, 79-82 (1997).
18. Kopecky, J., Clarke, G., Enerback, S., Spiegelman, B., & Kozak, L.P. Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. J. Clin. Invest. 96, 2914-2923 (1995).
19. Clapham, J.C. et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406, 415-418 (2000).
20. Li, B. et al. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat. Med. 6, 1115-1120 (2000).
21. Enerback, S. et al. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 387, 90-94 (1997).
22. Arsenijevic, D. et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat. Genet. 26, 435-439 (2000).
23. Vidal-Puig, A.J. et al. Energy metabolism in uncoupling protein 3 gene knockout mice. J. Biol. Chem. 275, 16258-16266 (2000).
24. Levine, J., Eberhardt, N. & Jensen, M. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 283, 212-214 (1999).
25. Ullrich, A. et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761 (1985).
26. Ebina, Y. et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Cell 40, 747-758 (1985).
27. Sun, X.J. et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77 (1991).
28. Sun, X.J. et al. Role of IRS-2 in insulin and cytokine signaling. Nature 377, 173-177 (1995).
29. Accili, D. et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nature Genet. 12, 106-109 (1996).
30. Michael, M. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87-97 (2000).
31. Kulkarni, R. et al. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96, 329-339 (1999).
32. Bruning, J. et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2, 559-569 (1998).
33. Fernandez, A. et al. Functional inactivation of the IGF-1 and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15, 1926-1934 (2001).
34. Mu, J., Brozinick, J., Valladares, 0., Bucan, M. & Birnbaum, M. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7, 1085-1094 (2001).
35. Bluher, M., Kahn, B. & Kahn, R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574 (2003).
36. Lauro, D. et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat. Genet. 20, 294-298 (1998).
37. Guerra, C. et al. Brown adipose tissue-specific insulin receptor knockout shows a diabetic phenotype without insulin resistance. J. Clin. Invest. 108, 1205-1213 (2001).
38. Tamemoto, H. et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 182-186 (1994).
39. Withers, D. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904 (1998).
40. Shulman, G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
41. Dresner A. et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259 (1999).
42. Perseghin, G. et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48, 1600-1606 (1999).
43. Petersen, K.F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140-1142 (2003).
44. Kim, J.K. et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA 98, 7522-7527 (2001).
45. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
46. Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
47. Dreyer, C. et al. Control of the peroxisomal P-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887 (1992).
48. Kliewer, S.A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci USA 91, 7355-7359 (1994).
49. Chawla, A., Repa, J.J., Evans, R.M. & Mangelsdorf, D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 294, 1866-1870 (2001).
50. Rosen E.D., Walkey, C.J., Puigserver, P. & Spiegelman, B.M. Transcriptional regulation of adipogenesis. Genes Dev. 14, 1293-1307 (2000).
51. Tontonoz, P., Hu, E. & Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
52. Barak, Y. et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595 (1999).
53. Rosen, E.D. et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617 (1999).
54. Kubota, N. et al. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609 (1999).
55. Agarwal, A.K. & Garg, A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87, 408-411 (2002).
56. Hegele, R.A., Cao, H., Frankowski, C., Mathews, S.T. & Leff, T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51, 3586-3590 (2002).
57. Savage, D.B. et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 52, 910-917 (2003).
58. Wu, Z. et al. Cross-regulation of C/EBP and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell 3, 151-158 (1999).
59. Rosen, E.D. et al. C/EBPalpha induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 16, 22-26 (2002).
60. Forman, B.M. et al. Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803-812 (1995).
61. Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARy). J. Biol. Chem. 270, 12953-12956 (1995).
62. Yamauchi, T. et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254 (2001).
63. Guan, H.-P., et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8, 1122-1128 (2002).
64. Peraldi P., Xu, M. & Spiegelman, B.M. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J. Clin. Invest. 100, 1863-1869 (1997).
65. Steppan, C.M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).
66. Rajala, M.W., Obici, S., Scherer, P.E. & Rossetti, L. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J. Clin. Invest. 111, 225-300 (2003).
67. Combs T.P., Berg A.H., Obici S., Scherer P.E. & Rossetti, L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108, 1875-1881 (2001).
68. Berg, A.H., Combs, T.P., Du, X., Brownlee, M. & Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953 (2001).
69. Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946 (2001).
70. Yamauchi, T. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002).
71. Yamauchi, T. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423, 762-769 (2003).
72. Ribon, V., Johnson, J.H., Camp, H.S. & Saltiel, A.R. Thiazolidinediones and insulin resistance: peroxisome proliferator activated receptor γ activation stimulates expression of the CAP gene. Proc. Natl. Acad. Sci. USA 95, 14751-14756 (1998).
73. Burant, C.F. et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100, 2900-2908 (1997).
74. Chao, L. et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228 (2000).
75. Gavrilova, O. et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276 (2003).
76. Kim, J.K. et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52, 1311-1318 (2003).
77. Miles, P.D., Barak, Y., He, W., Evans, R.M. & Olefsky, J.M. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105, 287-292 (2000).
78. Berger, J.P. et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol. Endocrinol. 17, 662-676 (2003).
79. Rangwala, S.M. et al. Genetic modulation of PPARg phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657-663 (2003).
80. Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W. & Kahn, R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953-959 (1998).
81. Matsusue, K, et al. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111, 737-747 (2003).
82. He, W. et al. Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA 100, 15712-15717 (2003).
83. Koutnikova, H. et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR γ hypomorphic mice. Proc. Natl. Acad. Sci. USA 100, 14457-14462 (2003).
84. Hevener, A.L. et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med. 9, 1491-1497 (2003).
85. Norris, A.W. et al. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112, 608-618 (2003).
86. Reddy, J.K. & Hashimoto, T. Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu. Rev. Nutr. 21, 193-230 (2001).
87. Kersten, S. et al. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489-1498 (1999).
88. Guerre-Millo, M, et al. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638-16642 (2000).
89. Chou, C.J. et al. WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. 277, 24484-24489 (2002).
90. Kim, H. et al. Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52, 1770-1778 (2003).
91. Peters, J.M. et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20, 5119-5128 (2000).
92. Barak, Y. et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA 99, 303-308 (2002).
93. Oliver, W.R. et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98, 5306-5311 (2001).
94. Wang, Y.-X. et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113, 159-170 (2003).
95. Puigserver, P. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829-839 (1998).
96. Muoio, D.M. et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPAR δ. J. Biol. Chem. 277, 26089-26097 (2002).
97. Dressel, U. et al. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 17, 2477-2493 (2003).
98. Luquet, S. et al. Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J. 17, 2299-2301 (2003).
99. Tanaka, T. et al. Activation of peroxisome proliferator-activated receptor β induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA 100, 15924-15929 (2003).
100. Gupta, R. et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10, 245-247 (2004).
101. Saez, E. et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med. 4, 1058-1061 (1998).
102. Sarraf, P. et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4, 1046-1052 (1998).
103. Min/+ mice. Nat. Med. 4, 1053-1057 (1998).
104. Lee, C.H. et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302, 453-457 (2003).
105. Ricote, M., Valledor, A.F. & Glass, C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 230-239 (2004).